These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1191 related items for PubMed ID: 23313382

  • 1. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R, Mirshahi S, Mirshahi P, Klein C, Jamshedov J, Chidiac J, Perzborn E, Mirshahi M, Soria C, Soria J.
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.
    Gronostaj K, Richter P, Nowak W, Undas A.
    Thromb Res; 2013 Mar; 131(3):262-7. PubMed ID: 23273404
    [Abstract] [Full Text] [Related]

  • 9. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC, Dieter JP, Strebel LC, Taylor TM, Muscolino G, Feinberg H, Le Breton GC.
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [Abstract] [Full Text] [Related]

  • 10. Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
    Wolzt M, Gouya G, Kapiotis S, Becka M, Mueck W, Kubitza D.
    Thromb Res; 2013 Aug; 132(2):240-7. PubMed ID: 23786894
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen.
    Hugenholtz GC, Macrae F, Adelmeijer J, Dulfer S, Porte RJ, Lisman T, Ariëns RA.
    J Thromb Haemost; 2016 May; 14(5):1054-66. PubMed ID: 26833718
    [Abstract] [Full Text] [Related]

  • 15. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome.
    Siudut J, Grela M, Wypasek E, Plens K, Undas A.
    J Thromb Haemost; 2016 Apr; 14(4):784-93. PubMed ID: 26786481
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FXIII polymorphisms, fibrin clot structure and thrombotic risk.
    Kobbervig C, Williams E.
    Biophys Chem; 2004 Dec 20; 112(2-3):223-8. PubMed ID: 15572253
    [Abstract] [Full Text] [Related]

  • 18. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
    Jansen JW, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman TA.
    Thromb Haemost; 1987 Apr 07; 57(2):171-5. PubMed ID: 2440124
    [Abstract] [Full Text] [Related]

  • 19. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
    He S, Johnsson H, Zabczyk M, Hultenby K, Cao H, Blombäck M.
    Br J Haematol; 2013 Mar 07; 160(6):806-16. PubMed ID: 23360261
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.